 | |
| Clinical data | |
|---|---|
| Other names | SC-6924; Manvene; Anvene;3-Methoxy-16α-methylestra-1,3,5(10)-triene-16β,17β-diol; 16α-Methylestriol 3-methyl ether; 16β-Hydroxy-16α-methylestradiol 3-methyl ether |
| Routes of administration | By mouth |
| Drug class | Estrogen;Estrogen ether |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C20H28O3 |
| Molar mass | 316.441 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Mytatrienediol (developmental code nameSC-6924; former tentative brand namesManvene,Anvene), also known as16α-methyl-16β-epiestriol 3-methyl ether or16β-hydroxy-16α-methylestradiol 3-methyl ether, is asyntheticsteroidalestrogen medication and anestrogen ether which was derived fromestriol and was developed for clinical use in the late 1950s but was never marketed.[1] It was investigated as a weak and mildly estrogenic medication for men to treatatherosclerosis, improveserumlipid profiles, and reduce the risk ofmyocardial infarction.[2][3][4][5][6][7] However, whilepreclinical research supported the profile of mytatriendiol as a weak estrogen, the medication was found inclinical trials to produce estrogenicside effects includingfeminization,breast pain, andgynecomastia in men similarly and comparably to other estrogens such asethinylestradiol andconjugated estrogens, and its side effects ultimately precluded its use.[8][3][2] The medication was also studied to treatbone pain in patients withmultiple myeloma,metastatic bone disease, andosteoporosis, with effectiveness seen.[9]
